Novo Nordisk receives important US approval for Levemir  

The FDA has granted Novo Nordisk marketing authorisation for its long-acting insulin analogue Levemir

Healthcare company Novo Nordisk has announced that it has received marketing authorisation for its long-acting insulin analogue, Levemir, from the US Food and Drug Administration (FDA). Levemir has already been approved for use in 37 countries, including in the 25 members of the European Union. Novo Nordisk expects to introduce Levemir on the US market within the next 12 months.

Kåre Schultz, executive vice president of Novo Nordisk, comments: "The US approval of Levemir is an important milestone for Novo Nordisk because it complements our portfolio of insulin analogues and thus paves the way for a continued expansion of our diabetes business in the US". The news is reported by national daily newspaper Jyllands-Posten.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs about 21,000 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×